Alloy Therapeutics Signs Collaboration And License Agreement With Takeda To Develop Takeda's Proprietary Induced Pluripotent Stem Cell Derived CAR-T Cell Platform And IPSC-Derived CAR-NK Platform
Alloy Therapeutics Signs Collaboration And License Agreement With Takeda To Develop Takeda's Proprietary Induced Pluripotent Stem Cell Derived CAR-T Cell Platform And IPSC-Derived CAR-NK Platform
Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK) to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies.
致力於普及尖端藥物發現技術的生物技術生態系統公司Alloy Therapeutics Inc.（「Alloy」）今天宣佈與武田製藥有限公司（紐約證券交易所代碼：TAK）達成戰略合作和許可協議，開發武田專有的誘導多能幹細胞（iPSC）衍生的CAR-T細胞平台（iCar-T）和iPSC衍生的CAR-NK平台（ICAR-NK）。Alloy將專注於加快關鍵療法的開發，以克服實體和血液學惡性腫瘤。
iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at Kyoto University. The core technology to differentiate iPSC into immune cells originates from CiRA's Shin Kaneko's laboratory. iCAR-T has potential to develop 'off-the-shelf' cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy.
iCAR-T 技術是武田與京都大學知識產權研究與應用中心 (CiRA) 之間的 t-Cira 聯合研究計劃的一部分開發的。將iPSC分化爲免疫細胞的核心技術源自CiRA的Shin Kaneko實驗室。與自體細胞療法相比，iCAR-T有可能開發 「現成的」 細胞療法，具有一流性能、增強效力，並顯著降低製造成本。
